Medical network on April 17 - officially announced national health insurance directory "supplement list". 

 

▍ local drug companies rob "home" 

 

14 in the evening, people club department released the 2017 edition of health insurance directory negotiating the final list of the drugs, 44 species were classified into the scope of health care medicine directory negotiations. 

 

This list is also quickly put an end to the after market for the expanded version of "health care market" the hypothesis that 44 varieties including local 18, 26 foreign investment; Corresponding to the 17 local pharmaceutical companies and 15 foreign-invested enterprises, a total of 32 drug firms shortlisted. 

 

And structurally worth attention is that 32 drug firms, domestic drug accounted for 53%, beyond the foreign enterprise; Local varieties, reached 41%, far beyond the parties before the market forecast for this number. 

 

Previously, the reports said, was published in the number of the list of drugs for 45 negotiations, only the number of native species to single digits. 

 

Including leaves pharmaceutical injections of paclitaxel liposome, jiangsu hengrui mesylate path for slice, simcere human recombinant endostatin injection of innovative drugs are going into the directory, as health supplement. 

 

 

(photo: large pharmaceutical jin-yang zhang team) 

 

Eventually released directory revealed a clear message, perhaps in has always been considered a multinational drug companies "home" negotiations medicine field, the comparative advantages of foreign and domestic gap are fuzzy, as the country of innovative medicine support kept increasing, a large number of domestic 1.1 class new medicine and a variety of high quality reproductions of the original and alternative market, may be coming faster and more violent than expected. 

 

In the current macro-reforms, on the other hand, has not yet been fully promote, not produce fundamental shock to the hospital drug use existing pattern at present, insurance market is still the drug firms value most gold content is also the most key markets. 

 

Concerned about multiple factors such as price maintenance, wait for a long time of multinational pharmaceutical companies are just beginning to take price in quantity and price in the market attempt to pace, it is the only hope that through negotiations channel can be supplemented into health care, however, now more than half of the local drug firms to bargaining market segmentation, will the original has not yet been blood blade battlefield immediately became tense. 

 

▍ health-care docking is the key 

 

In fact, as a further price rises to the rights of public administration reform and exploration, price negotiation system's original intention is the way through negotiated the price higher patented drugs and drug prices have fallen to a reasonable interval, exclusive production has been the international practice, only just beginning to try to nationwide fall to the ground in the country. 

 

On May 17, 2016, the first batch of national health insurance directory negotiation results were announced, five varieties of the first landing. 

 

First-line treatment chronic hepatitis b drug tenofovir ester, ek for non-small cell lung cancer targeted therapy drugs, the treatment and three kinds of drug reduction reached 67%, 54% and 54%, respectively, among them, tenofovir ester in price after be your lowest price for the varieties of the world. 

 

For there is no precedent for this system, national negotiations many drug firms more or wait. 

 

Public information, five varieties of the negotiations, only zhejiang beida a local pharmaceutical companies; And because of problem such as price reduction ratio, there is also a well-known multinational pharmaceutical companies in the last stage of negotiations from unacceptable steep price. 

 

Enterprise concerns very reality, after the price cut, if a local health care can't smooth docking reimbursement, and how to make up for the loss reduction. 

 

"We have been looking at the first actually participate in the negotiations (price) the trend of the enterprise, for now, the most worried about health care does not solve problems, if we save a space to talk to health department, also not reality." After the talks catalogue published in 2016, the first, at a pharmaceutical company has been actively pay attention to progress to the media said. 

 

Between a year, from the five varieties to 44 varieties of varieties across and drug companies behind the attitude change, is the health care community is the final settlement. 

 

During this year's "two sessions", li bin, director of the national health development planning commission said at a news conference, negotiating the price of drugs in 2016 countries, already all into the scope of coverage, the public can be carried out in accordance with the proportion of reimbursement. 

 

"How much drug firms to keep prices down, to decide whether the drug to negotiate access to health care system, the government how many purchase quantity each year. The government procurement, the drug companies are more willing to put the price more lower. Drug companies can accept the single biggest reason, however, still in order to expand the market and government negotiations." School of public health, Peking University professor Zhou Zijun think after an interview with the media.